JETEMA (216080) Fundamentals 2026 — Revenue Analysis | SniperIQ
JETEMA (216080) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩155.7B, trading at ₩4185.00 on the KOE. This SniperIQ fundamentals page covers JETEMA's valuation, profitability (net margin -6.6%), revenue (₩76.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is JETEMA's market cap?
JETEMA (216080) has a market capitalization of approximately ₩155.7B, trading at ₩4185.00 on the KOE. Market cap moves with the live share price.
What is JETEMA's P/E ratio?
JETEMA's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is JETEMA?
JETEMA runs a net profit margin of -6.6%, a gross margin of 44.1%, and an operating margin of 4.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does JETEMA generate?
JETEMA reported revenue of ₩76.9B for fiscal year 2025, with net income of -₩6.6B and earnings per share (EPS) of -184.02. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does JETEMA pay a dividend?
JETEMA does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is JETEMA financially healthy?
JETEMA carries a debt-to-equity ratio of 1.61x and a current ratio of 0.43x, with a market beta of 0.64. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is JETEMA a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For JETEMA (216080) the key facts are: market cap ₩155.7B, revenue ₩76.9B, 52-week range 4040-11280. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track JETEMA's full fundamentals live
Get JETEMA's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.